MedTrace Logo

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

NCT04031703 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 647

Last updated 2020-04-24

No results posted yet for this study

Summary

This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer

Conditions

Interventions

DRUG

Paclitaxel

Paclitaxel chemotherapy (injection)

DRUG

Carboplatin

Carboplatin chemotherapy (injection)

DRUG

Epirubicin

Epirubicin chemotherapy (injection)

DRUG

Cyclophosphamide

Cyclophosphamide chemotherapy (injection)

DRUG

5-fluorouracil

5-fluorouracil chemotherapy (injection)

DRUG

Docetaxel

Docetaxel chemotherapy (injection)

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhi-Ming Shao · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2016-04-20
Completion
2016-04-20

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04031703 on ClinicalTrials.gov